Business
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board
Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease; Phase 2 ulcerative colitis IND
About this update from Palisade Bio, Inc.
[{"type":"text","content":"Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precision medicine and advanced, non-invasive disease assessment. His appointment further enhances Palisade’s clinical and translational expertise as the Company prepares to advance PALI-2108 into Phase 2 development in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD). “As we transition into Phase 2 development, optimizing patient selection, endpoint strategy, and disease monitoring will be central to demonstrating meaningful clinical benefit,” said Mitch Jones, MD, PhD, President and Chief Medical Officer of Palisade Bio. “Dr. Verstockt is a global leader in precision medicine and non-invasive assessment in IBD. His expertise in advanced imaging, biomarker integration, and multi-omics research will be highly valuable as we design studies intended to efficiently demonstrate durable efficacy and disease modification in both UC and FSCD.” About Bram Verstockt, MD, PhD Dr. Verstockt is an IBD staff physician and professor in the Department of Gastroenterology and Hepatology at University Hospitals Leuven and KU Leuven, Belgium. His clinical and translational research centers on precision medicine in IBD, with a focus on disease heterogeneity, biomarker development, and non-invasive disease monitoring techniques, including intestinal ultrasound and advanced radiologic modalities. He has played a leading role in international collaborations applying multi-omics, proteomics, and organoid-based platforms to better characterize treatment response and disease behavior in IBD. Dr. Verstockt is also a co-founder of the COLLIBRI proteomics consortium, which advances biomarker discovery and translational research across inflammatory diseases. “Preci...